Skip to content Skip to footer

Ipamorelin: Mechanism, Research Applications and Handling Requirements

Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, with a molecular weight of about 711.9 daltons. It is studied as an agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), the G protein-coupled receptor that is also activated by the natural peptide ghrelin. Researchers use it to examine receptor signalling, growth hormone release from pituitary cells, selectivity among secretagogues, and the effect of non-natural amino acids on peptide stability. This article covers its structure and origin, its mechanism, the key published laboratory studies, its research applications, and the purity, storage and handling requirements that apply to the material.

What is ipamorelin?

Ipamorelin, also known by the development code NNC 26-0161, is classed as a growth hormone secretagogue and, more specifically, a ghrelin receptor agonist. It is a short peptide of five residues with the formula C38H49N9O5. Unlike most research peptides, only two of its residues are standard L-amino acids. The sequence begins with α-aminoisobutyric acid (Aib), an achiral amino acid with two methyl groups on its α-carbon that restricts backbone flexibility and hinders protease attack. It continues with L-histidine, D-2-naphthylalanine (D-2-Nal), D-phenylalanine and L-lysine, and the C-terminus is amidated. The D-amino acids and the bulky naphthyl side chain are important to receptor binding and to resistance against enzymatic degradation.

The compound came from a medicinal chemistry programme at Novo Nordisk. Growth hormone-releasing peptides (GHRPs) were first developed by Cyril Bowers and colleagues from enkephalin analogues, beginning in the late 1970s, and GHRP-6, a hexapeptide, became a standard tool. The receptor was cloned in 1996, and in 1999 Kojima and colleagues identified ghrelin as its natural ligand. The Novo Nordisk group, led by Kjeld Raun, reported ipamorelin in 1998. It was identified within a series of compounds lacking the central dipeptide Ala-Trp of GHRP-1, and the authors described it as the first GHRP-receptor agonist with a selectivity for growth hormone release similar to that of GHRH.

A regulatory note is worth making early. Ipamorelin is not, to the author’s knowledge, an authorised medicine in the UK, and it is among the growth hormone secretagogues named by the World Anti-Doping Agency in its Prohibited List. UK buyers should check the current position with the Medicines and Healthcare products Regulatory Agency. Nothing in this article concerns use in people.

Mechanism of action

Ipamorelin acts at GHS-R1a, a class A G protein-coupled receptor with seven transmembrane domains. The receptor is expressed in the anterior pituitary and in parts of the hypothalamus, among other tissues. When an agonist binds, the receptor couples mainly to Gq/11, activating phospholipase C, which generates inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and diacylglycerol activates protein kinase C. The rise in intracellular calcium triggers exocytosis of stored growth hormone from somatotrophs, and the receptor can also engage arrestin-mediated pathways that govern desensitisation and internalisation. GHS-R1a is also known for substantial constitutive activity, which complicates the interpretation of assays where baseline signalling is high.

The receptor system is distinct from that of growth hormone-releasing hormone. GHRH binds a separate class B receptor that signals through Gs and cyclic AMP, and the two pathways can act in concert on the same somatotroph. The original pharmacological profiling of ipamorelin used GHRP and GHRH antagonists to separate the pathways. The results demonstrated that ipamorelin, like GHRP-6, stimulates growth hormone release through a GHRP-like receptor.

What distinguishes ipamorelin in the literature is selectivity. Earlier secretagogues such as GHRP-6 also acted on other endocrine endpoints in animal models, and ipamorelin was characterised as unusually restricted to growth hormone release. That description comes from the original study, and subsequent work should be consulted for how robust the selectivity is across species and models.

The structure also shapes its handling. The Aib residue and the two D-amino acids slow proteolysis, so the peptide persists in biological media longer than an all-L pentapeptide would. The hydrophobic naphthyl group affects solubility and gives the molecule a strong UV signal, which is useful for chromatographic detection.

What the research shows

Four areas of published work underpin the use of ipamorelin in laboratories. Readers should consult the primary papers for methods and data.

The first is the original characterisation by Raun and colleagues, published in the European Journal of Endocrinology in 1998. The paper describes the development and pharmacology of ipamorelin, a pentapeptide that displayed high growth hormone-releasing potency and efficacy both in vitro and in vivo. The experiments combined pituitary cell assays with animal models and compared ipamorelin with GHRP-6 and with GHRH. The abstract concludes that its selectivity for growth hormone release resembles that of GHRH. The record is on PubMed.

The second is the discovery of ghrelin by Kojima and colleagues in Nature in 1999, which identified the natural ligand of the receptor on which ipamorelin acts. The group purified an endogenous ligand for an orphan receptor from rat stomach, a peptide of 28 amino acids in which serine 3 carries an n-octanoyl group. The acylated peptide released growth hormone in vivo and in vitro, and the octanoyl modification was essential for activity. The study explains why synthetic secretagogues of different chemical classes converge on a single receptor, and the record is on PubMed.

The third is a group of rodent studies from the same Novo Nordisk programme on skeletal endpoints. Work published around 1999 examined longitudinal bone growth in hypophysectomised rats, a standard model in which the pituitary has been removed so that growth hormone-dependent responses can be isolated, and a later study in 2001 looked at bone formation in adult rats given glucocorticoids. These papers used the compound as a pharmacological tool in animal models, and they are described here in general terms because the details and dosing schemes should be read in the original publications.

The fourth is pharmacokinetic and pharmacodynamic modelling work on growth hormone-releasing peptides, together with receptor structure-activity studies, which have clarified why the D-amino acids and the aminoisobutyric acid residue matter for potency and persistence. As with the rodent studies, the specifics depend on the model and assay, so primary sources should be consulted.

Research applications

Ipamorelin is used in several well-defined laboratory contexts. In receptor pharmacology, it serves as an agonist in assays on cell lines expressing GHS-R1a, with readouts such as calcium flux, inositol phosphate accumulation and arrestin recruitment. It is often run alongside ghrelin, GHRP-6 and other agonists to compare potency, efficacy and signalling bias, and alongside inverse agonists to probe the receptor’s constitutive activity.

In primary pituitary cultures and pituitary-derived cell lines, it is applied to study growth hormone release, desensitisation and the interaction with GHRH and somatostatin signalling. In peptide chemistry, ipamorelin is a model for studying how non-proteinogenic residues influence conformation and proteolytic stability, and for developing methods that separate and quantify stereoisomers.

In analytical chemistry, it is used as a reference material. Because secretagogues appear on anti-doping lists, forensic and anti-doping laboratories need well-characterised standards for developing and validating liquid chromatography and mass-spectrometry methods. For that purpose, identity and purity documentation is as important as in any cell-based study.

UK purchasers should also consider the regulatory framework. The MHRA decides case by case whether a product is a medicine, looking at labelling, packaging, promotional literature and advertisements, including websites. Its borderline products guidance explains the approach. A research-use-only designation carries weight only when everything about how the material is supplied is consistent with laboratory use, and dosing or protocol language anywhere on a supplier’s site would weigh against it. This is general information, not legal advice, and institutions should involve their compliance staff.

Purity, storage and handling

Verification begins with reversed-phase HPLC, usually with UV detection at 214 or 220 nm, which separates the target from deletion sequences, truncated chains and incompletely deprotected by-products. The naphthyl group gives ipamorelin a strong chromophore, so detection is sensitive, and purity is reported as the percentage of total peak area belonging to the target. A figure of 98% or higher is commonly specified for cell-based and receptor assays. HPLC does not prove identity, so it should be paired with mass spectrometry confirming that the observed mass matches the theoretical value, with a protonated ion near m/z 712.

Stereochemistry deserves particular attention. Two of the five residues are D-amino acids, and a small amount of racemisation during synthesis would produce diastereomers that may differ sharply in receptor activity while sharing the same mass. Standard HPLC may resolve some of them, but chiral amino acid analysis or a dedicated chromatographic method provides stronger evidence. A batch-specific certificate of analysis matters because synthesis is never perfectly repeatable. Two lots of the same sequence can differ in purity, counter-ion content, water content and net peptide content, and a generic specification sheet cannot capture that variation. A proper certificate lists the lot number, chromatogram, mass-spectrometry result and analysis date, so a result can be traced to a specific vial. Because the sequence depends on non-proteinogenic residues whose stereochemistry must be correct, batch-level HPLC and mass-spectrometry verification matters more here than with sequences built only from standard L-amino acids. UK laboratories sourcing Ipamorelin should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and the supplier checks are set out in How to buy best peptides.

Lyophilised peptides are most stable when dry, sealed and cold. Storage at -20°C is the usual recommendation for the long term, and -80°C is sometimes preferred for sensitive material. Vials should be brought to room temperature in a desiccator before opening, because condensation introduces moisture that promotes hydrolysis. The short sequence of ipamorelin contains no cysteine, methionine or tryptophan, which makes it less prone to oxidation than many peptides, though the imidazole ring of histidine and the lysine side chain can still react over long periods.

Reconstituted peptides are far less stable than the dry powder. Stock solutions are normally prepared in sterile water or a suitable buffer, divided into single-use aliquots and frozen to avoid repeated freeze-thaw cycles. The hydrophobic naphthyl and phenyl groups can promote adsorption to plastic, so low-binding tubes are advisable at low concentrations, and a small proportion of an organic solvent such as DMSO may be needed for stock solutions, matched against the tolerance of the assay. Stability in solution is sequence-specific, and researchers should consult supplier data and validate it under their own conditions.

Light sensitivity is a further consideration. The naphthyl and phenyl rings can undergo photo-oxidation, so vials are best stored in the dark or in amber glass, and bench exposure should be kept short. Each aliquot should be labelled with the date, lot number and concentration so that any later anomaly can be traced.

Frequently asked questions

What is the molecular weight and sequence of ipamorelin?

Ipamorelin is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, with the formula C38H49N9O5 and a molecular weight of about 711.9 daltons. It contains three non-standard residues: α-aminoisobutyric acid, D-2-naphthylalanine and D-phenylalanine. Mass spectrometry on each batch should match the theoretical mass, and stereochemical purity also matters.

Which receptor does ipamorelin act on?

Ipamorelin is an agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), the receptor activated by ghrelin. GHS-R1a signals mainly through Gq, and activation raises intracellular calcium in receptor-expressing cells. Researchers measure it with calcium flux, inositol phosphate and growth hormone release assays in cell models.

How should lyophilised ipamorelin be stored?

Keep the sealed vial dry, protected from light and at -20°C for long-term storage. Allow it to reach room temperature in a desiccator before opening so condensation does not add moisture. Divide reconstituted stock into single-use aliquots, freeze them, and avoid repeated freeze-thaw cycles, since stability in solution is far lower than that of the powder.

How is ipamorelin different from GHRP-6?

Both act on the GHS-R1a receptor, but ipamorelin is a pentapeptide developed from a series lacking the central Ala-Trp dipeptide of GHRP-1, and in the original characterisation it showed selectivity for growth hormone release similar to GHRH. GHRP-6 is a hexapeptide with a different sequence and a broader profile.

The compound discussed in this article is supplied for in-vitro laboratory research only and is not for human or veterinary use.

Leave a comment

99% Purity Guarantee
Trusted By Researchers
★★★★★
Celebrating 500,000 Orders
Third party verified